Tekmira Pharmaceuticals presented animal data today on it's now LNP RNAi treatment for HBV at the Oligonucleotide conference in San Diego. It showed a 1 long knockdown at only 1mg per kg in the mouse model and 2 logs in the woodchuck, human trials are slated for early 2015. These results blow ARC-520 away
"These Hepatitis B results from Tekmira show huge promise for a multitude of reasons. For starters, the clinical trial models were performed with the help of Bristol-Myers (BMY); that meant that Tekmira was able to use more advanced pre-clinical trial models that mimic human results. Secondly Tekmira ran the trial using three RNAi triggers -- three gene targets -- that results in a more potent and broad gene knockdown compared to other RNAi companies that only ran with one trigger. Finally Tekmira impressed the most for the fact that one single dose at only 1 mg/kg was able to achieve a log 1 reduction."